Marcelo Bravo
Directeur Général chez OXvax Ltd
Profil
Marcelo Leonardo Bravo is the founder of Abaco Capital Plc (founded in 2009) and OXvax Ltd (founded in 2021).
At Abaco Capital Plc and OXvax Ltd, he held no titles and was not active at Abaco Capital Plc.
Currently, Mr. Bravo is a Director at Oxford Pharmascience Ltd.
(since 2008).
Mr. Bravo's former position was as Chief Executive Officer & Director at DeepMatter Group Plc.
Mr. Bravo has an undergraduate degree from Case Western Reserve University, a graduate degree from London Business School, and an undergraduate degree from The College of Wooster.
Postes actifs de Marcelo Bravo
| Sociétés | Poste | Début |
|---|---|---|
Oxford Pharmascience Ltd.
 Oxford Pharmascience Ltd. Pharmaceuticals: MajorHealth Technology Oxford Pharmascience Ltd. operates as a drug development firm. The company was founded on February 8, 2008 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 08/02/2008 |
OXvax Ltd
 OXvax Ltd BiotechnologyHealth Technology OXvax Ltd is a British company that develops cancer vaccines. The company was founded in 2021 by Paul J. Fairchild, Marcelo Leonardo Bravo, Tim Davies. Marcelo Leonardo Bravo has been the CEO since 2021. | Directeur Général | 15/02/2021 |
Anciens postes connus de Marcelo Bravo
| Sociétés | Poste | Fin |
|---|---|---|
| DEEPMATTER GROUP PLC | President | 01/10/2009 |
| ABACO CAPITAL PLC | Fondateur | - |
Formation de Marcelo Bravo
| The College of Wooster | Undergraduate Degree |
| Case Western Reserve University | Undergraduate Degree |
| London Business School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
DeepMatter Group Plc
 DeepMatter Group Plc Packaged SoftwareTechnology Services DeepMatter Group Plc is engaged in the development of a number of projects targeting new chemicals, materials, formulations, and pharmaceuticals in commercial areas. It operates through the following segments: DeepMatter and InfoChem. The DeepMatter segment owns, develops and is in the early stage of exploiting intellectual property, software, hardware and data analysis capabilities combined as a visionary, disruptive platform called DigitalGlassware, enabling step changes in productivity and discovery for scientists in the pharma and life science sectors. The InfoChem segment develops and commercialises cheminformatics software to handle, store and retrieve chemical structures and reactions for application in pharma, life sciences, and scientific publications. The company was founded by Jon-Paul Griffiths and Mark G. Moloney on June 13, 2006 and is headquartered in Glasgow, the United Kingdom. | Technology Services |
Abaco Capital Plc
 Abaco Capital Plc Financial ConglomeratesFinance Abaco Capital Plc was a drug development company, which was engaged in re-developing approved drugs using proprietary formulation technologies. The company was founded by Marcelo Bravo and Nigel Theobald on October 7, 2009 and was headquartered in London, the United Kingdom. | Finance |
Oxford Pharmascience Ltd.
Oxford Pharmascience Ltd. Pharmaceuticals: MajorHealth Technology Oxford Pharmascience Ltd. operates as a drug development firm. The company was founded on February 8, 2008 and is headquartered in London, the United Kingdom. | Health Technology |
OXvax Ltd
OXvax Ltd BiotechnologyHealth Technology OXvax Ltd is a British company that develops cancer vaccines. The company was founded in 2021 by Paul J. Fairchild, Marcelo Leonardo Bravo, Tim Davies. Marcelo Leonardo Bravo has been the CEO since 2021. | Health Technology |
